Skip to main content
Signal8

Invion Limited (IVIXF)

Invion Limited, an Australian biopharmaceutical firm currently in the clinical development phase, is dedicated to pioneering light-activated therapies for a diverse range of cancers. Its leading therapeutic candidate, IVX-PDT, functions as a photosensitizer agent aimed at treating not only skin cancers but also various solid tumors, such as those found in the lung, prostate, ovaries, and in cases of mesothelioma. The company engages in strategic collaborations to further its research and development efforts. It holds an R&D agreement with the Hudson Institute of Medical Research, partnering on several projects related to the Photosoft technology for cancer treatment. Additionally, Invion has established a research pact with the Peter MacCallum Cancer Centre to carry out pre-clinical and in-vitro studies focusing on its IVX-PDT photodynamic therapy for ano-genital cancers, including penile and anal forms. Established in 2000, Invion Limited is based in Melbourne, Australia.

Sector: Drug Manufacturers - Specialty & Generic

Industry: Drug Manufacturers - Specialty & Generic

Invion Limited logo

Invion Limited

OTC:IVIXFHealthcare
Mkt Cap-
EV-
Float59.25M
O/S110.55M
Inst Own-
Net Cash/Sh-$0.01
Dilution
Financials Summary
Revenue$266K
Net Income-$3.9M
Total Assets$5.65M
Free Cash Flow-$1.64M
Debt & Equity
Debt 23%
Equity 77%
Total Debt$1.07M
Total Equity$3.68M
Shares Outstanding
Short Interest
Split History1 split · 1 reverse
2-year cumulative
1:100

Nasdaq bars a compliance period at 1:250

  1. 1:100Reverse split
    Nov 20, 2024100 shares → 1
Balance Sheet Details
Assets$5.65M
Liabilities$1.97M
Accounts Receivable$0
Accounts Payable$464K
Inventory$0
PP&E (Net)$4K
Goodwill$0
Intangible Assets$5.16M
Income Statement
PeriodFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
CurrencyUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Period Ending2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-30
Revenue$266K$0$2.46M$2.73M$2.27M$1.75M$2.39M$2.72M$545K$0$0
YoY Growth---9.9%20.4%29.8%-26.9%-12.1%399.8%---
Cost of Revenue$1.19M$849K-$1.23M$1.93M$1.6M$1.14M$1.08M$1.57M$275K$955K$983K
Gross Profit-$925K-$849K$3.69M$804K$669K$608K$1.31M$1.16M$545K-$955K-$983K
Gross Margin-347.7%-150.0%29.4%29.5%34.7%54.7%42.5%100.0%--
Research and Development$1.03M$849K$2.69M$1.93M$1.6M$1.14M$1.07M$1.57M$269K$24K$969K
Selling, General, and Administrative$1.97M$1.78M$1.51M$1.45M$1.98M$1.58M$1.84M$2.71M$868K$621K$2.66M
Other$0$0$1.51M$0$0$0$0$0$0$0$0
Total Operating Expenses$2.99M$2.63M$5.71M$3.38M$3.58M$2.72M$2.91M$4.27M$1.14M$645K$3.63M
Operating Income (EBIT)-$3.92M-$3.48M-$3.78M-$1.1M-$1.6M-$1.18M-$707K-$1.77M-$710K-$1.6M-$4.62M
Operating Margin-1472.2%--153.7%-40.2%-70.5%-67.5%-29.5%-64.8%-130.2%--
Interest Expense$240K$457K$0$0$0$0$0$0$87K$111K$124K
Interest Income$423$2K$33K$22K$37$65$376$936$792$322$2K
Other Income (Expense)$21K-$2.32M$33K$22K$55K$67K$370K-$19K-$96K-$3.35M$78K
Income Before Tax (EBT)-$3.9M-$5.8M-$3.75M-$1.08M-$1.55M-$1.11M-$657K-$1.79M-$805K-$4.95M-$4.54M
Income Tax Expense$0$0$0$0$0$0$0$0-$121K-$3.26M-$1.23M
Net Income-$3.9M-$5.8M-$5.63M-$1.08M-$1.55M-$1.11M-$657K-$747K-$3.6M-$1.69M-$3.31M
Net Income Margin-1464.2%--228.5%-39.3%-68.1%-63.6%-27.4%-27.4%-660.2%--
Supplementary Data
EPS-0.04-0.08-0.06-0.02-0.03-0.02-0.01-0.01-0.09-0.11-0.24
Diluted EPS-0.04-0.08-0.06-0.02-0.03-0.02-0.01-0.01-0.09-0.11-0.24
Weighted Average OS90.05M72.05M64.24M64.20M61.17M55.26M55.01M54.95M38.14M15.89M13.63M
EBITDA-$2.73M-$2.63M-$3.05M-$640K-$1.3M-$972K-$520K-$1.54M-$2.9M-$3.89M-$3.43M
EBITDA Margin-1024.5%--123.8%-23.4%-57.4%-55.6%-21.7%-56.6%-532.0%--
Balance Sheet
PeriodFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
CurrencyUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Period Ending2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-30
Assets
Current Assets
Cash and Cash Equivalents$410K$560K$784K$2.72M$5.85M$778K$426K$541K$2.14M$704K$326K
Short-Term Investments$0$0$0$0$0$0$0$0$0$0$0
Cash and Short-Term Investments$410K$560K$784K$2.72M$5.85M$778K$426K$541K$2.14M$704K$326K
Accounts Receivable$0$0$1.21M$1.08M$97K$8K$187K$85K$68K$0$482K
Inventory$0$0$0$0$0$0$0-$0$0$2$0
Other Current Assets$73K$55K$87K$0$0$0$0$0$0$0$0
Total Current Assets$482K$614K$2.08M$3.84M$5.97M$808K$631K$661K$2.26M$772K$869K
Long-Term Assets
Property, Plant & Equipment Net$4K$14K$39K$39K$331$769$3K$3K$0$2K$4K
Goodwill$0$0$0$0$0$0$0$0$0$0$0
Intangible Assets$5.16M$5.62M$13.33M$8.81M$7.86M$3.43M$3.33M$3.33M$5.38M$3.68M$8.01M
Long-Term Investments$0$0$0$0$0$0$0$0$0$0$40K
Deferred Tax Assets$0$0$0$0$0$0$0$0$0$0$0
Other Long-Term Assets$0$0$0$0$0$0$0$257K$0$1$0
Total Long-Term Assets$5.17M$5.63M$13.37M$8.85M$7.86M$3.43M$3.34M$3.59M$5.38M$3.69M$8.05M
Other Assets$0$0$0$0$0$0$0$0$0$0$0
Total Assets$5.65M$6.25M$15.45M$12.69M$13.83M$4.24M$3.97M$4.25M$7.65M$4.46M$8.92M
Liabilities
Current Liabilities
Accounts Payable$464K$357K$721K$79K$221K$449K$106K$34K$220K$117K$205K
Short-Term Debt$1.07M$0$0$0$0$0$0$2$0$964K$90K
Current Income Tax Payable$0$0$0$0$0$0$0$0$0$0$0
Current Unearned Revenue$0$0$0$0$0$0$8K$35K$655K$2$0
Other Current Liabilities$272K$270$87K$167K$139K$302K$145K$128K$158K$288K$233K
Total Current Liabilities$1.97M$815K$1.01M$433K$319K$639K$225K$424K$1.32M$1.38M$475K
Long-Term Liabilities
Long-Term Debt$0$0$0$0$0$0$0$0$0$0$2.75M
Long-Term Unearned Revenue$0$0$0$0$0$0$0$0$0$0$0
Long-Term Deferred Tax Liabilities$0$0$0$0$0$0$0$0$482K$0$3.09M
Other Long-Term Liabilities$0$0$0$0$0$0$0$0$6K$0$0
Total Long-Term Liabilities$0$0$0$0$0$0$0$0$488K$1.91M$5.84M
Other Liabilities$0$0$0$0$0$0$0$0$0$0$0
Total Liabilities$1.97M$815K$1.01M$433K$319K$639K$225K$424K$1.8M$3.29M$6.31M
Stockholders' Equity
Preferred Stock$0$0$0$0$0$0$0$0$0$0$0
Common Stock$105.56M$99.52M$148.35M$97.82M$101.12M$98.32M$89.89M$91.62M$97.63M$94.88M$91.62M
Retained Earnings-$102.94M-$95.13M-$136.08M-$86.9M-$90.28M-$96.54M-$87.52M-$104.01M-$109.35M-$109.79M-$104.94M
Comprehensive Income & Other$1.06M$1.04M$2.16M$1.32M$2.67M$1.82M$1.37M$16.22M$17.56M$16.08M$15.92M
Other Stockholders' Equity$1.06M$1.04M$2.16M$1.32M$2.67M$1.82M$1.37M$16.22M$17.56M$16.08M$15.92M
Total Equity$3.68M$5.43M$14.44M$12.25M$13.51M$3.6M$3.74M$3.83M$5.84M$1.17M$2.61M
Minority Interest$0$0$0$0$0$0$0$0$0$0$0
Total Liabilities and Equity$5.65M$6.25M$15.45M$12.69M$13.83M$4.24M$3.97M$4.25M$7.65M$4.46M$8.92M
Supplementary Data
Total Debt$1.07M$0$0$0$0$0$0$0$0$2.87M$2.83M
Net Debt$661K-$560K-$784K-$2.72M-$5.85M-$778K-$426K-$541K-$2.14M$2.17M$2.51M
Cash Flow Statement
PeriodFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
CurrencyUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Period Ending2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-30
Operating Activities
Net Income-$3.9M-$5.8M-$3.75M-$1.08M-$1.55M-$1.11M-$657K-$1.79M-$685K-$1.69M-$3.31M
Depreciation & Amortization$1.19M$3.17M$544K$455K$291K$209K$191K$217K$118K$955K$983K
Deferred Income Tax$0$0$0$0$0$0$0$0$0$0$0
Stock-Based Compensation$0$62K$0$247K$662K$675K$642K$0$0$0$0
Changes in Working Capital:
  Accounts Receivable-$15K-$3K-$1.64M-$1.09M-$6K$74K-$51K-$1K-$70K$532K-$181K
  Inventory$0$0$0$0$0$0$0$0$0$0$0
  Accounts Payable-$5K$0$209K$110K-$268K$370K-$181K-$219K$483K$25K$1.27M
  Other Working Capital$16K$16K$16K$102K-$73K$98K-$48K-$613K$749K$3K-$36K
Total Working Capital Change-$4K$12K-$1.42M-$875K-$347K$542K-$280K-$833K$1.16M$561K$1.05M
Other Non-Cash Items$1.07M$603K$3.03M$41K$175K$812-$2K$925K-$74K$1.33M-$704K
Net Cash from Operating-$1.64M-$1.95M-$1.6M-$1.21M-$765K$314K-$105K-$1.48M$522K-$190K-$2.85M
Investing Activities
Capital Expenditures-$48K$0-$600K-$1.72M-$5M$0$0-$4K$0$0$0
Acquisitions$0$0$0$0$0$0$0-$5K$0$0$101
Purchases of Investments$0$0$0$0$0$0$0$0$0$0$0
Sales of Investments$0$0$0$0$0$0$0$0$0$41K$19K
Other Investing Activities$0$0$0$0$0$0$0-$8K$0$0-$0
Net Cash from Investing-$48K$0-$600K-$1.72M-$5M$0$0-$10K$0$41K$19K
Financing Activities
Debt Repaid--------$1.24M-$38K$974K
Common Stock Issuance$653K$1.53M$0$0$16.64M$0$0$0$3.21M$657K$3.08M
Common Stock Repurchases$0$0$0$0-$842K$0$0$0-$286K-$15K-$212K
Dividends Paid$0$0$0$0$0$0$0$0$0$0$0
Other Financing Activities$277K$955K$0$0$0$0$0$0$347K$0$249K
Net Cash from Financing$1.51M$2M$0$0$10.9M$0$0$0$937K$521K$1.41M
Forex Effect$29K-$7K$2K-$204K-$63K$39K$0-$757$0$0$0
Net Change in Cash-$149K$37K-$2.2M-$3.13M$5.07M$352K-$115K-$1.6M$1.43M$378K-$1.42M
Supplementary Data
Operating Cash Flow-$1.64M-$1.95M-$1.6M-$1.21M-$765K$314K-$105K-$1.48M$522K-$190K-$2.85M
Capital Expenditure-$3K$4-$900K-$1.72M-$5M$4$0-$4K$0$0$0
Free Cash Flow-$1.64M-$1.95M-$2.5M-$2.92M-$5.77M$314K-$105K-$1.48M$522K-$190K-$2.85M
Cash at Beginning$559K$523K$4.08M$5.85M$778K$426K$541K$2.14M$704K$326K$1.75M
Cash at End$410K$560K$784K$2.72M$5.85M$778K$426K$541K$2.14M$704K$326K